Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Down-Turner syndrome (45,X/47,XY,+21): case report and review].
Ryu SW, Lee G, Baik CS, Shim SH, Kim JT, Lee JS, Lee KA. Ryu SW, et al. Among authors: baik cs. Korean J Lab Med. 2010 Apr;30(2):195-200. doi: 10.3343/kjlm.2010.30.2.195. Korean J Lab Med. 2010. PMID: 20445340 Free article. Review. Korean.
New Immuno-oncology Targets and Resistance Mechanisms.
Tokaz MC, Baik CS, Houghton AM, Tseng D. Tokaz MC, et al. Among authors: baik cs. Curr Treat Options Oncol. 2022 Sep;23(9):1201-1218. doi: 10.1007/s11864-022-01005-8. Epub 2022 Aug 18. Curr Treat Options Oncol. 2022. PMID: 35980521 Review.
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Houvras Y, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Kong S, Zalutskaya A, Louie-Gao M, Boral AL, Mazières J. Griesinger F, et al. Among authors: baik cs. Ann Oncol. 2022 Nov;33(11):1168-1178. doi: 10.1016/j.annonc.2022.08.002. Epub 2022 Aug 13. Ann Oncol. 2022. PMID: 35973665 Free article. Clinical Trial.
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC.
Johnson BE, Baik CS, Mazieres J, Groen HJM, Melosky B, Wolf J, Zadeh Vosta Kolaei FA, Wu WH, Knoll S, Ktiouet Dawson M, Johns A, Planchard D. Johnson BE, et al. Among authors: baik cs. JTO Clin Res Rep. 2022 Apr 6;3(5):100324. doi: 10.1016/j.jtocrr.2022.100324. eCollection 2022 May. JTO Clin Res Rep. 2022. PMID: 35592617 Free PMC article.
Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer.
Bowen SR, Hippe DS, Thomas HM, Sasidharan B, Lampe PD, Baik CS, Eaton KD, Lee S, Martins RG, Santana-Davila R, Chen DL, Kinahan PE, Miyaoka RS, Vesselle HJ, Houghton AM, Rengan R, Zeng J. Bowen SR, et al. Among authors: baik cs. Adv Radiat Oncol. 2021 Nov 21;7(2):100857. doi: 10.1016/j.adro.2021.100857. eCollection 2022 Mar-Apr. Adv Radiat Oncol. 2021. PMID: 35387421 Free PMC article.
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
Chalker C, Voutsinas JM, Wu QV, Santana-Davila R, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Eaton KD, Rodriguez CP. Chalker C, et al. Among authors: baik cs. Cancer Med. 2022 Nov;11(22):4104-4111. doi: 10.1002/cam4.4722. Epub 2022 Mar 29. Cancer Med. 2022. PMID: 35349227 Free PMC article.
39 results